Table 2.
Laboratory Indicators of Patients with COVID-19 in Wuhan.
| Laboratory Tests | Reference values | No. of patients tested | Value, median (IQR) | Definition of value deviation from the reference | No. of patients with value deviation from reference (%) |
|---|---|---|---|---|---|
| Hematologic | |||||
| White blood cells, × 109/mL | 3.5–9.5 | 121 | 5.73 (4.21–8.30) | >10 | 16 (13.2) |
| Neutrophils, × 109/mL | 1.8–6.3 | 121 | 4.06 (2.51–6.56) | >6.5 | 33 (27.3) |
| Lymphocytes, × 109/mL | 1.1–3.2 | 121 | 0.94 (0.68–1.24) | <1.1 | 81 (66.9) |
| Monocytes, × 109/mL | 0.1–0.6 | 121 | 0.44 (0.30–0.57) | >0.65 | 22 (18.2) |
| eosinophils, × 109/mL | 0.02–0.52 | 121 | 0.02 (0.00–0.67) | >0.55 | 39 (32.2) |
| basophils, × 109/mL | 0–0.06 | 121 | 0.02 (0.01–0.03) | >0.065 | 5 (4.1) |
| Platelets, × 109/mL | 125–350 | 121 | 204.0 (161.0–257.5) | <100 | 12 (9.9) |
| Hemoglobin, g/L | 115–150 | 121 | 121.0 (104.0–137.0) | <110 | 41 (33.9) |
| Biochemical | |||||
| ALT, U/L | 7–40 | 121 | 24.0 (16.0–42.5) | >80 | 16 (13.2) |
| AST, U/L | 13–35 | 121 | 30.0 (20.0–46.5) | >70 | 8 (6.6) |
| Albumin, g/L | 40–55 | 121 | 36.2 (32.65–39.30) | <35 | 27 (22.3) |
| Creatinine, μM | 41–81 | 120 | 65.0 (51.5–78.5) | >150 | 10 (8.3) |
| Estimated GFR, mL/min | >90 | 121 | 93.86 (78.46–104.90) | <90 | 48 (39.7) |
| CK-MB, U/L | 40–200 | 121 | 63.0 (38.5–96.5) | >200 | 12 (9.9) |
| LDH, U/L | 120–160 | 121 | 296 (210–403) | >250 | 75 (62.0) |
| Coagulation function | |||||
| PT, sec | 9–13 | 118 | 12.20 (11.40–13.20) | >16 | 3 (2.5) |
| APTT, sec | 25–31.3 | 118 | 28.30 (25.73–30.70) | >42 | 2 (1.7) |
| D-dimer, μg/mL | 0–0.55 | 117 | 1.23 (0.50–4.19) | >0.6 | 85 (72.6) |
| FDP, mg/L | 0–5 | 112 | 4.90 (1.51–13.32) | >6 | 52 (46.4) |
| Infection-related indices | |||||
| hs-CRP, mg/L | 0–5 | 121 | NA* | >5 | 100 (82.6) |
| Procalcitonin, ng/ml | 0–2 | 103 | 1.19 (0.16–5.40) | >3 | 43 (41.7) |
| IgM-NCOV, AU/mL | <10 | 96 | 24.03 (9.95–63.02) | >15 | 59 (62.1) |
| IgG-NCOV, AU/mL | <10 | 95 | 150.87 (113.84–178.05) | >15 | 3 (3.1) |
| Immune-related indices | |||||
| CD3, /μL | 723–2737 | 119 | 519.0 (359.0–877.0) | <700 | 80 (67.2) |
| CD4, /μL | 404–1612 | 119 | 320.0 (212.0–515.0) | <400 | 75 (63.0) |
| CD8, /μL | 12–39 | 119 | 199.0 (113.0–316.0) | <10 | 0 (0.0) |
| CD19, /μL | 80–616 | 118 | 128.0 (92.0–190.0) | <80 | 24 (20.3) |
| CD16+CD56, /μL | 84–724 | 119 | 107.0 (65.0–189.0) | <80 | 42 (35.3) |
| C3, g/L | 0.9–1.8 | 111 | 1.01 (0.88–1.12) | <0.9 | 30 (27.0) |
| C4, g/L | 0.1–0.4 | 111 | 0.27 (0.20–0.34) | <0.1 | 1 (0.9) |
| Interleukin-2, pg/mL | ≤ 11.4 | 87 | 3.67 (3.28–4.00) | >12 | 3 (3.4) |
| Interleukin-4, pg/mL | ≤ 12.9 | 86 | 3.16 (2.88–3.50) | >12 | 0 (0.0) |
| Interleukin-6, pg/mL | ≤ 20.0 | 105 | 13.54 (6.12–8.00) | >22 | 37 (35.2) |
| Interleukin-10, pg/mL | ≤ 5.9 | 87 | 6.33 (5.41–8.00) | >6 | 56 (64.4) |
| Tumor necrosis factor, pg/mL | ≤ 5.5 | 87 | 3.21 (2.91–4.78) | >6 | 19 (21.8) |
| Interferon-γ, pg/mL | ≤ 18 | 87 | 3.24 (1.95–4.24) | >20 | 5 (5.7) |
ALT, alanine aminotransferase; AST, aspartate aminotransferase; CK-MB, creatine kinase muscle-brain isoform; LDH, lactate dehydrogenase; PT, prothrombin time; APTT, activated partial thromboplastin time; FDP, fibrinogen degradation products; hs-CRP, high-sensitivity C-reactive protein; GFR, glomerular filtration rate; C3, complement protein C3; C4, complement protein C4; IQR, interquartile range.
*
The original data of hs-CRP are categorical variables without specific values.